BRPI0918629B8 - sal de n-[6-cis-2,6-dimetilmorfolin-4-il]piridina-3-il]-2-metil-4'-(trifluormetóxi)[1-1'-bifenil]-3-carboxamida, e composição farmacêutica - Google Patents

sal de n-[6-cis-2,6-dimetilmorfolin-4-il]piridina-3-il]-2-metil-4'-(trifluormetóxi)[1-1'-bifenil]-3-carboxamida, e composição farmacêutica

Info

Publication number
BRPI0918629B8
BRPI0918629B8 BRPI0918629A BRPI0918629A BRPI0918629B8 BR PI0918629 B8 BRPI0918629 B8 BR PI0918629B8 BR PI0918629 A BRPI0918629 A BR PI0918629A BR PI0918629 A BRPI0918629 A BR PI0918629A BR PI0918629 B8 BRPI0918629 B8 BR PI0918629B8
Authority
BR
Brazil
Prior art keywords
trifluoromethoxy
cis
methyl
dimethylmorpholin
biphenyl
Prior art date
Application number
BRPI0918629A
Other languages
English (en)
Inventor
Singh Bajwa Joginder
Murlidhar Waykole Liladhar
De La Cruz Marilyn
Wu Raeann
Kay Dodd Stephanie
Original Assignee
Novartis Ag
Sun Pharma Global Fze
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41228716&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0918629(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Sun Pharma Global Fze filed Critical Novartis Ag
Priority to BR122020009045-6A priority Critical patent/BR122020009045B1/pt
Publication of BRPI0918629A2 publication Critical patent/BRPI0918629A2/pt
Publication of BRPI0918629B1 publication Critical patent/BRPI0918629B1/pt
Publication of BRPI0918629B8 publication Critical patent/BRPI0918629B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

sal de n-[6-cis-2,6-dimetilmorpolin-sal] piridina-3-4l]-2-metila(trifluormetôxndi, 1 -bifenil]-s-carboxamida, e composição farmacêutica à presente invenção se refere a sais de n-[o-cis-2,s-dimetimortolin- s-ll oiridina-3-il-2-metil-4 (trifluormetós»xi)[1, 1 -bifenili-3-carboxamida, assim como a composições farmacêuticas compreendendo os mesmos.
BRPI0918629A 2008-09-17 2009-09-15 sal de n-[6-cis-2,6-dimetilmorfolin-4-il]piridina-3-il]-2-metil-4'-(trifluormetóxi)[1-1'-bifenil]-3-carboxamida, e composição farmacêutica BRPI0918629B8 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122020009045-6A BR122020009045B1 (pt) 2008-09-17 2009-09-15 Uso de sais de n-[6-cis-2,6-dimetilmorfolin-4-il]piridina-3-il]-2-metil-4'-(trifluormetóxi)[1,1'- bifenil]-3-carboxamida no tratamento de carcinoma e outros tumores

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9758008P 2008-09-17 2008-09-17
US61/097,580 2008-09-17
PCT/US2009/056918 WO2010033481A1 (en) 2008-09-17 2009-09-15 Salts of n-[6-cis-2,6-dimethylmorpholin-4yl)pyridine-3yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide

Publications (3)

Publication Number Publication Date
BRPI0918629A2 BRPI0918629A2 (pt) 2020-10-27
BRPI0918629B1 BRPI0918629B1 (pt) 2021-04-13
BRPI0918629B8 true BRPI0918629B8 (pt) 2021-05-25

Family

ID=41228716

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0918629A BRPI0918629B8 (pt) 2008-09-17 2009-09-15 sal de n-[6-cis-2,6-dimetilmorfolin-4-il]piridina-3-il]-2-metil-4'-(trifluormetóxi)[1-1'-bifenil]-3-carboxamida, e composição farmacêutica
BR122020009045-6A BR122020009045B1 (pt) 2008-09-17 2009-09-15 Uso de sais de n-[6-cis-2,6-dimetilmorfolin-4-il]piridina-3-il]-2-metil-4'-(trifluormetóxi)[1,1'- bifenil]-3-carboxamida no tratamento de carcinoma e outros tumores

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122020009045-6A BR122020009045B1 (pt) 2008-09-17 2009-09-15 Uso de sais de n-[6-cis-2,6-dimetilmorfolin-4-il]piridina-3-il]-2-metil-4'-(trifluormetóxi)[1,1'- bifenil]-3-carboxamida no tratamento de carcinoma e outros tumores

Country Status (39)

Country Link
US (3) US8063043B2 (pt)
EP (1) EP2342198B1 (pt)
JP (2) JP4897938B2 (pt)
KR (2) KR101129088B1 (pt)
CN (1) CN102159570B (pt)
AR (2) AR073591A1 (pt)
AU (1) AU2009293444B2 (pt)
BR (2) BRPI0918629B8 (pt)
CA (1) CA2736751C (pt)
CL (1) CL2011000551A1 (pt)
CO (1) CO6351744A2 (pt)
CR (1) CR20110126A (pt)
CU (1) CU23860B1 (pt)
DK (1) DK2342198T3 (pt)
DO (1) DOP2011000082A (pt)
EA (1) EA020048B1 (pt)
EC (1) ECSP11010985A (pt)
ES (1) ES2418485T3 (pt)
GE (1) GEP20125592B (pt)
HN (1) HN2011000745A (pt)
HR (1) HRP20130597T1 (pt)
IL (1) IL211412A (pt)
JO (1) JO2889B1 (pt)
MA (1) MA32717B1 (pt)
MX (1) MX2011002805A (pt)
MY (1) MY151100A (pt)
NI (1) NI201100051A (pt)
NZ (1) NZ591420A (pt)
PE (1) PE20110292A1 (pt)
PH (1) PH12012500399A1 (pt)
PL (1) PL2342198T3 (pt)
PT (1) PT2342198E (pt)
SI (1) SI2342198T1 (pt)
SM (1) SMT201300072B (pt)
SV (1) SV2011003857A (pt)
TW (1) TWI367883B (pt)
UA (1) UA103049C2 (pt)
WO (1) WO2010033481A1 (pt)
ZA (1) ZA201101579B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
CN101993415B (zh) * 2010-09-15 2013-08-14 北京韩美药品有限公司 作为Hedgehog通路抑制剂的化合物以及包含该化合物的药物组合物及其应用
AU2014220339B2 (en) * 2013-02-25 2016-12-01 Sun Pharmaceutical Industries Limited Oral formulation and suspension of an oncology drug
WO2015092720A1 (en) * 2013-12-19 2015-06-25 Novartis Ag Metabolites of sonidegib (lde225)
US10266523B2 (en) 2015-03-30 2019-04-23 Crystal Pharmatech Co., Ltd. Crystaline forms of N-[6-(cis-2,6-dimethylmorpholine-4-yl)pyridine-3-yl]-2-Methyl-4′-(trifluoromethoxy) [1,1′-biphenyl]-3-Methanamide monophosphate, and process of preparation thereof
PL3302428T3 (pl) 2015-06-04 2026-04-13 Sol-Gel Technologies Ltd. Preparaty do zastosowania miejscowego do dostarczania związków inhibitora hedgehog i ich zastosowanie
ES3057783T3 (en) 2016-03-15 2026-03-04 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
WO2017163258A1 (en) * 2016-03-22 2017-09-28 Msn Laboratories Private Limited Process for the preparation of n-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2- methyl-4'-(trifiuoromethoxy) [1,1' -biphenyi]-3-carboxamide and its polymorphs thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ546001A (en) * 2003-10-02 2009-09-25 Pharmacia & Upjohn Co Llc Salts and polymorphs of a pyrrole-substituted indolinone compound
GB0412468D0 (en) * 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
UA93548C2 (uk) * 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
PE20080948A1 (es) * 2006-07-25 2008-09-10 Irm Llc Derivados de imidazol como moduladores de la senda de hedgehog

Also Published As

Publication number Publication date
US20120035174A1 (en) 2012-02-09
SV2011003857A (es) 2011-05-16
AU2009293444A1 (en) 2010-03-25
MX2011002805A (es) 2011-04-11
MY151100A (en) 2014-04-15
HK1156628A1 (en) 2012-06-15
NZ591420A (en) 2012-07-27
BR122020009045B1 (pt) 2022-08-02
US20110178085A1 (en) 2011-07-21
US8063043B2 (en) 2011-11-22
PH12012500399A1 (en) 2014-04-28
HRP20130597T1 (en) 2013-07-31
WO2010033481A1 (en) 2010-03-25
CR20110126A (es) 2011-04-27
ZA201101579B (en) 2011-11-30
GEP20125592B (en) 2012-07-25
CA2736751C (en) 2012-10-23
CN102159570B (zh) 2014-01-15
ECSP11010985A (es) 2011-05-31
PE20110292A1 (es) 2011-05-17
AU2009293444B2 (en) 2012-03-15
EP2342198B1 (en) 2013-04-03
JP4897938B2 (ja) 2012-03-14
MA32717B1 (fr) 2011-10-02
US20120214810A1 (en) 2012-08-23
DOP2011000082A (es) 2011-04-15
CN102159570A (zh) 2011-08-17
CU20110055A7 (es) 2011-12-28
KR20110056325A (ko) 2011-05-26
HN2011000745A (es) 2014-01-06
JO2889B1 (en) 2015-03-15
PT2342198E (pt) 2013-07-10
SMT201300072B (it) 2013-09-06
CU23860B1 (es) 2013-02-26
EA020048B1 (ru) 2014-08-29
NI201100051A (es) 2011-09-08
PL2342198T3 (pl) 2013-08-30
ES2418485T3 (es) 2013-08-14
CO6351744A2 (es) 2011-12-20
DK2342198T3 (da) 2013-07-01
KR20120015363A (ko) 2012-02-21
EP2342198A1 (en) 2011-07-13
AR113778A2 (es) 2020-06-10
TWI367883B (en) 2012-07-11
IL211412A0 (en) 2011-05-31
TW201016686A (en) 2010-05-01
AR073591A1 (es) 2010-11-17
JP2012502912A (ja) 2012-02-02
JP2012097104A (ja) 2012-05-24
BR122020009045A2 (pt) 2020-11-10
BRPI0918629A2 (pt) 2020-10-27
UA103049C2 (uk) 2013-09-10
EA201100501A1 (ru) 2011-10-31
CL2011000551A1 (es) 2011-07-15
IL211412A (en) 2014-07-31
CA2736751A1 (en) 2010-03-25
SI2342198T1 (sl) 2013-07-31
KR101129088B1 (ko) 2012-03-23
BRPI0918629B1 (pt) 2021-04-13

Similar Documents

Publication Publication Date Title
BRPI0918629B8 (pt) sal de n-[6-cis-2,6-dimetilmorfolin-4-il]piridina-3-il]-2-metil-4'-(trifluormetóxi)[1-1'-bifenil]-3-carboxamida, e composição farmacêutica
BRPI0814252B8 (pt) composição farmacêutica aquosa estável compreendendo natalizumabe, dose unitária, e seringa pré-cheia
GT200900057A (es) 4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil}amino)-3-fluorofenoxi]-n-metilpiridina-2-carboxamida monohidrato
BR112014016165A2 (pt) compostos de benzaldeído substituído e métodos para seu uso no aumento da oxigenação do tecido
JOP20150301B1 (ar) بنزاميدات مستبدلة مع 3،1-ثيازول-2- يل
BR112015001327A2 (pt) complexo cristalino de 1-ciano-2-(4-ciclopropil-benzil) -4-(beta-d-glicopiranos-1-il) -benzeno, métodos para sua preparação e o uso do mesmo para preparar medicamentos
UY32174A (es) Nuevos heterociclos sustituidos, composiciones farmaceuticas conteniendolos, procedimientos de preparacion y aplicaciones
MX2020003112A (es) Composiciones de biguanida y metodos para tratar trastornos metabolicos.
UY35492A (es) Compuestos novedosos
EA201301240A1 (ru) Полиморфная форма бензоата линаглиптина
BR112015022095A8 (pt) composição farmacêutica, método de fabricação, composição eutética e uso de composições contendo hcl ciclobenzabrina e manitol
MA32369B1 (fr) Composes de benzene sulfonamide thiazole et oxazole
BR112015005972A2 (pt) derivados do tipo amida de ácido benzoimidazol-carboxílico como moduladores do receptor apj
BR112013027670A2 (pt) "composto de amida, composição farmacêutica e medicamento que o compreende e antagonista de rory"
BR112012022873A2 (pt) formulações orais e sais lipofílicos de metilnaltrexona
MA32383B1 (fr) DÉRIVÉS D'INDAZOLES à SUBSTITUTIONS PHÉNYLE ET BENZODIOXYNYLE
BR112012009214A2 (pt) compostos
BR112014015568A2 (pt) compostos carbamato de fenila para uso em prevenção ou tratamento de epilepsia
UA109661C2 (uk) Фармацевтична композиція співкристалів трамадолу і коксибів
BR112014015845A2 (pt) derivados de azetidina, composições farmacêuticas e seu uso
BR112014002025A2 (pt) partículas que compreendem compostos ativos com base em poliacrilato
MX374468B (es) Composicion farmaceutica acuosa semisolida que contiene tapentadol.
BR112012021657B8 (pt) Composto, agente farmacêutico, agente para conferir kokumi , e, tempero
BR112014002674A2 (pt) 3-(bifenil-3-il)-4-hidróxi-8-metóxi-1-azaspiro[4.5]dec-3-en-2-onas substituídas
BR112012007888A2 (pt) "métodos de tratamento usando anticorpos anti-ldl oxidada".

Legal Events

Date Code Title Description
B12F Other appeals [chapter 12.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: SUN PHARMA GLOBAL FZE (AE)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/09/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/09/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF